Recent Pharmacological Advances of Drugs and Vaccines Used in COVID-19 | Chapter 13 | Highlights on Medicine and Medical Science Vol. 6

A pandemic disease caused by a coronavirus named Corona Virus Disease 2019 (COVID-19) is spreading over the world, causing asymptomatic severe acute respiratory syndrome (SARS) termed SARS-CoV-2. Finding effective medications for preventive and treatment offers a significant problem for scientists, researchers, and practitioners. Clinicians are striving to acquire accurate information for efficient treatment and establishing an appropriate vaccine system for the prevention of illness spread by using a large amount of clinical data obtained from many SARS-CoV-2 afflicted persons. Because no effective medicines to treat and prevent SARS-CoV-2 have been established to date, there is a chance for new virology researchers to make an attempt at this critical time. Two strategies are now in use. The first is to create entirely new molecules to prevent and treat this disease, while the second is to evaluate the efficacy of currently available antivirals and other medications for possible recovery and prevention. This includes evaluating a variety of antivirals (Remdesivir, Favipiravir, and others) as well as antimalarials (Chloroquine, Hydroxychloroquine, and others) for prospective therapy. According to studies, the antiviral Remdesivir is the most promising treatment. Remdesivir has demonstrated that it has the capability to regulate COVID-19 in vitro. Randomized trials are now being conducted on the medication. Different antiviral therapy options are used under an urgent exploration plan until a generally acknowledged medicine reaches the global market. In this chapter, we look at the most recent research findings on COVID-19 systematic therapies from a variety of research labs throughout the world. The chapter also includes a description of diverse clinical research experiences, interim results, and therapy recommendations to battle the novel coronavirus outbreak based on pharmacotherapeutic analysis, as well as insights into global efforts to produce a COVID vaccine.

Author (s) Details

Edwin Dias
Department of Paediatrics, Srinivas Institute of Medical Sciences and Research Centre, Mangalore, Karnataka State, India and College of Allied Health Sciences, Srinivas University, Mangalore, India.

Archana Aithal
Srinivas Institute of Pharmacy, India.

Ranjit Shail
NHS, South London / St. George’s University of London, UK.

View Book :- https://stm.bookpi.org/HMMS-V6/article/view/2114